D.A. Wallach Explains Why Biotech VC Is So Different

Most people think of venture capital as funding software startups or, these days, some new AI tool. But VC also plays a major role in developing new medicines and treatments. That’s the world of D.A. Wallach — though he didn’t start there. Before becoming a biotech investor, Wallach was the lead singer of the indie rock band Chester French. So how did he make the leap from music to venture capital? How does he spot promising biotech opportunities? What does it actually take to bring a new drug to market? And how does biotech investing differ from traditional VC? We talk to the co-founder of Time BioVentures about all of this — plus we get his thoughts on AI’s impact on music and a special performance.

Have a question for Joe and Tracy? Now's your chance to be the perfect guest - record a voice memo with your name, age, location and question and email to oddlots@bloomberg.net for a chance to be included in the holiday AMA episode.

Read More:
Big Pharma’s Patent Cliff Puts China Front and Center
Novartis Strikes Deal With UK Biotech for Up To $1.7 Billion

Join the conversation: discord.gg/oddlots

Only Bloomberg.com subscribers can get the Odd Lots newsletter in their inbox — now delivered every weekday — plus unlimited access to the site and app. bloomberg.com/subscriptions/oddlots

See omnystudio.com/listener for privacy information.